Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation

Explore ASCO 2026 head and neck cancer updates: novel bispecific antibodies, neoadjuvant IO response rates, and IO-radiation timing insights.